Eupraxia Pharmaceuticals Inc. Common Stock
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. The company's proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. Its lead product candidates include EP-104IAR, which is in Phase III clinical trial for the treatment of unm… Read more
Eupraxia Pharmaceuticals Inc. Common Stock (EPRX) - Net Assets
Latest net assets as of September 2025: $123.06 Million USD
Based on the latest financial reports, Eupraxia Pharmaceuticals Inc. Common Stock (EPRX) has net assets worth $123.06 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($128.50 Million) and total liabilities ($5.43 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $123.06 Million |
| % of Total Assets | 95.77% |
| Annual Growth Rate | 29.88% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 1572.16 |
Eupraxia Pharmaceuticals Inc. Common Stock - Net Assets Trend (2017–2024)
This chart illustrates how Eupraxia Pharmaceuticals Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Eupraxia Pharmaceuticals Inc. Common Stock (2017–2024)
The table below shows the annual net assets of Eupraxia Pharmaceuticals Inc. Common Stock from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $31.84 Million | +3468.09% |
| 2023-12-31 | $892.33K | -90.86% |
| 2022-12-31 | $9.76 Million | -48.95% |
| 2021-12-31 | $19.12 Million | +188.25% |
| 2020-12-31 | $-21.66 Million | -19.49% |
| 2019-12-31 | $-18.13 Million | -58.55% |
| 2018-12-31 | $-11.44 Million | -323.94% |
| 2017-12-31 | $5.11 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Eupraxia Pharmaceuticals Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 11089506200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $116.36 Million | 348.33% |
| Other Comprehensive Income | $-4.16 Million | -12.45% |
| Other Components | $52.21 Million | 156.29% |
| Total Equity | $33.40 Million | 100.00% |
Eupraxia Pharmaceuticals Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Eupraxia Pharmaceuticals Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Wemade Co.Ltd
KQ:112040
|
$282.96 Million |
|
Five Point Holdings LLC
NYSE:FPH
|
$282.96 Million |
|
Cre8 Direct Ningbo Co Ltd
SHE:300703
|
$282.96 Million |
|
Flughafen Wien Aktiengesellschaft
PINK:FGWLF
|
$283.03 Million |
|
Plan B Media Public Company Limited
BK:PLANB-R
|
$282.66 Million |
|
Value Partners Group Ltd
PINK:VPGLF
|
$282.55 Million |
|
Siglent Technologies Co Ltd
SHG:688112
|
$282.51 Million |
|
SELECT HARVEST
F:H0I
|
$282.46 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Eupraxia Pharmaceuticals Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,216,207 to 33,404,803, a change of 31,188,596 (1407.3%).
- Net loss of 36,674,941 reduced equity.
- New share issuances of 54,558,610 increased equity.
- Other comprehensive income decreased equity by 1,454,003.
- Other factors increased equity by 14,758,930.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-36.67 Million | -109.79% |
| Share Issuances | $54.56 Million | +163.33% |
| Other Comprehensive Income | $-1.45 Million | -4.35% |
| Other Changes | $14.76 Million | +44.18% |
| Total Change | $- | 1407.30% |
Book Value vs Market Value Analysis
This analysis compares Eupraxia Pharmaceuticals Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.70x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 16.31x to 7.70x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $0.46 | $7.58 | x |
| 2018-12-31 | $-0.86 | $7.58 | x |
| 2019-12-31 | $-1.38 | $7.58 | x |
| 2020-12-31 | $-1.65 | $7.58 | x |
| 2021-12-31 | $1.40 | $7.58 | x |
| 2022-12-31 | $0.55 | $7.58 | x |
| 2023-12-31 | $0.09 | $7.58 | x |
| 2024-12-31 | $0.98 | $7.58 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Eupraxia Pharmaceuticals Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -109.79%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.05x
- Recent ROE (-109.79%) is above the historical average (-215.28%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -73.28% | 0.00% | 0.00x | 0.98x | $-4.98 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-12.08 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.60 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.89 Million |
| 2021 | -90.37% | 0.00% | 0.00x | 1.56x | $-20.03 Million |
| 2022 | -175.38% | 0.00% | 0.00x | 2.46x | $-19.54 Million |
| 2023 | -1273.38% | 0.00% | 0.00x | 9.14x | $-28.44 Million |
| 2024 | -109.79% | 0.00% | 0.00x | 1.05x | $-40.02 Million |
Industry Comparison
This section compares Eupraxia Pharmaceuticals Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Eupraxia Pharmaceuticals Inc. Common Stock (EPRX) | $123.06 Million | -73.28% | 0.04x | $282.93 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |